RBV Capital

At RBV Capital, we are building a diversified portfolio of early-stage breakthrough assets

Our investment strategy focuses on innovative science addressing critical unmet medical needs, and relies on selecting strong management teams with a clear vision

We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, and medical device companies

Immusoft and Takeda Collaborate to Discover and Develop Cell Therapies for Rare Neurometabolic Disorders

Immusoft’s Immune System Programming (ISP™) technology platform has been designed to address the challenges associated with current cell therapies

Pipeline Therapeutics Appoints Scott Oross as General Counsel

SAN DIEGO, June 25, 2021 – Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced that Scott Oross has been appointed as General Counsel

Immusoft Announces Formation Of Scientific Advisory Board

SEATTLE–Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs